Home » Topics » BioWorld Science

BioWorld Science
RSS

Cereno reports results from first clinical study of CS-1

July 3, 2018

Bacteriophages adjuvant therapy tested in patients with severe staphylococcal sepsis

July 3, 2018

Gazyva receives approval in Japan

July 3, 2018

Nipro applies for approval of human stem cell therapy product for spinal cord injury

July 3, 2018

Cell therapies wake up and smell the coffee

July 3, 2018

Separating the good, the bad and the indifferent in neurodegeneration

July 3, 2018

From Adam's rib to Miss Piggy's jaw

July 3, 2018

Imfinzi approved in Japan for the treatment of unresectable stage III NSCLC

July 2, 2018

LEO Pharma initiates phase I study of LEO-138559

July 2, 2018

JCR initiates phase II study of JR-141 as treatment of Hunter syndrome in Brazil

July 2, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
Recludix presents STAT1/3 inhibitors for dermatological diseases
BioWorld Science
Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.